Syk kinase inhibitors for rheumatoid arthritis: Trials and tribulations

Arthritis and Rheumatism

Volumn 63, Issue 2, 2011, Pages 329-330

  Boers, Maarten ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FOSTAMATINIB; GLUCOCORTICOID; IMATINIB; METHOTREXATE; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; DRUG INDICATION; EDITORIAL; ERYTHROCYTE SEDIMENTATION RATE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OXAZINES; PRODRUGS; PROTEIN-TYROSINE KINASES; PYRIDINES; RISK ASSESSMENT;

EID: 79551668315     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30109     Document Type: Editorial

References (9)

1. Wilske KR, Healey LA,. Remodeling the pyramidâa concept whose time has come. J Rheumatol 1989; 16: 565-7.
2. Boers M,. Understanding the window of opportunity concept in early rheumatoid arthritis [editorial]. Arthritis Rheum 2003; 48: 1771-4.
3. Rivera J, Colbert RA,. Healing the Syk through kinase inhibitors. N Engl J Med 2010; 363: 1362-4.
4. Cha HS, Boyle DL, Inoue T, Schoot R, Tak PP, Pine P, et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006; 317: 571-8.
5. Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 2007; 124: 244-57.
6. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58: 3309-18.
7. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB,. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010; 363: 1303-12.
8. Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011; 63: 337-45.
9. Pocock SJ, Assmann SE, Enos LE, Kasten LE,. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002; 21: 2917-30.